Special Issue "Recent Advancements in Research and Therapy of Ocular Neovascular Diseases"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 December 2020).
Interests: cancer; Alu RNA; Age-related Macular Degeneration (AMD); angiogenesis; Epithelial-to-Mesenchymal Transition (EMT); non-coding RNAs
Aberrant ocular neovascularization is a common denominator of many vision-threatening diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macula edema (DME), central retinal vein occlusion (CRVO), retinopathy of prematurity (ROP), and corneal neovascularization. The prevalence of some of these pathologies is destined to increase in the next few years, as a consequence of exponential population aging.
Anti-angiogenesis agents have revolutionized the treatment of ocular neovascular diseases. Their delivery by repeated intravitreal injections blocks the growth of pathological vessels preventing blindness and, in many cases, restoring vision. Despite this clinical success, many patients do not experience significant visual improvement and important side effects have been reported. Moreover, drug delivery by repeated intravitreal injections may generate devastating ocular complications. Accordingly, identification of new molecular mechanisms and of new targets governing ocular pathological neovascularization, as well as of new drugs that can be delivered by alternative routes of administration, is strongly in demand.
This Special Issue will include research articles, reviews, and short communications providing insight on the following:
- Recent advancements of molecular mechanisms governing the physiopathology of ocular neovascularization at genetic, biochemical, and cellular levels to evaluate their impact on disease development and progression;
- The druggability of new discovered targets;
- New therapeutic molecules that allow for alternative routes of administration for intraocular delivery or that require a very limited number of intraocular injections;
- Therapeutic interventions and clinical perspectives for ocular neovascular diseases.
Dr. Sandro De Falco
Dr. Valeria Tarallo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- ocular neovascular diseases
- angiogenesis and vasculogenesis
- growth factors and cytokines
- VEGF family
- molecular signaling
- mutations/polymorphisms of genes
- biochemical pathways
- endothelial cells
- inflammatory cells